Duvelisib

Drug Profile

Duvelisib

Alternative Names: ABBV-954; INK-1197; IPI-145

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Intellikine
  • Developer AbbVie; Dana-Farber Cancer Institute; Infinity Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Nonsteroidal anti-inflammatories; Purines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Follicular lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase I Haematological malignancies; Lymphoma
  • Preclinical Solid tumours
  • Discontinued Allergic asthma; Rheumatoid arthritis

Most Recent Events

  • 01 Feb 2017 AbbVie completes a phase I trial in Lymphoma (In adults, In the elderly) in Japan (PO)
  • 09 Jan 2017 Infinity Pharmaceuticals terminates the FRESCO trial in Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA and Hungary due to the shift of focus to the studies which can enable registration of duvelisib (NCT02605694) (EudraCT2015-004729-15)
  • 05 Dec 2016 Updated efficacy and adverse event data from the phase II DYNAMO trial in Non-Hodgkin Lymphoma presented at the the 58th Annual Meeting of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top